www.fdanews.com/articles/149542-oncolytics-sharply-overvalued-following-reo-018-trial-failure

Oncolytics Sharply Overvalued Following REO 018 Trial Failure

September 18, 2012

Investors apparently have not quite understood what was said recently in Oncolytics Biotech’s update on their Phase III trial of Reolysin (REO 018).
Seeking Alpha